INTRODUCTION
The incidence of diabetes mellitus (DM) worldwide was 9% in the adult population, including 90% of patients have type 2 diabetes. A similar situation exists as to Ukraine, where nowadays are more than 1.3 million patients with type 2 diabetes and control epidemiological studies argue, that the true prevalence of the disease at least are in three times higher [1] .
Medical and social severity of type 2 diabetes is caused not only by prevalence of this disease, but also by the development of a large number of complications, primarily related to the impairment of endothelial microvasculature vessels, which is based on hyperglycemia and intensification of lipid peroxidation (LPO) [2] . In the pathogenesis of type 2 diabetes is activated by excessive formation of reactive oxygen species, leading to an intensification of LPO and oxidative stress, which takes a leading role in the development of complications [8] [9] [10] . Proved, that type 2 diabetes -a free radical pathology [3] . Intensification of LPO and oxidative stress development starts before the clinical manifestation of type 2 diabetes and during early years of the disease [4] , but in patients with more than 10 years -is reduced. The degree of oxidative stress is closely associated with the weakening of enzymatic antioxidant system (AOS), disease duration and degree of decompensating of carbohydrate metabolism.
Gene PPARG is a major factor in the regulation of proliferation of adipocytes, as it increases the expression of the protein transporter of fatty acids, expression and activity of acetyl-CoA synthase, fosfatidilinozitol-3-kinase, gene expres-sion adiponectin, glucose transporter (GLUT-4), inhibits expression leptin gene, is involved in the regulation of protein oxidative phosphorylation, inhibits the expression in adipose tissue tumor necrosis factor-alpha, which is accompanied by a decrease in insulin resistance and an increase in insulin secretion β-cells. Associative impact polymorphic marker rs1801282 gene PPARG on the development of type 2 diabetes was confirmed in studies at European and Russian populations [5] . According to our previous studies, we found an association 12Pro allele of polymorphism rs1801282 gene PPARG with type 2 diabetes [6] .
Localization polymorphism rs1801282 of gene PPARG -Chr.3: 12393125 on NCBI Build 37. Sikvens areas analyzed AACTCTGGGA-GATTCTCCTATTGAC [C/G] CAGAAAGC-GATTCCTTCACTGATAC, polymorphic codon CCA / GCA. This polymorphism is a Single nucleotide polymorphism C to G, as a result, there is a replacement of the amino acid proline to alanine at position 12 in the protein gamma receptor, which activates peroxisome proliferation (PPARG). Ancestral allele is C and allele G -minor. According to MAF Source: 1000 Genomes (http://www.1000genomes.org/node/506) last frequency is T=0.0703/352.
Publication of results of studies on Chinese populations indicate, that the variant Pro 12 →Pro of polymorphism rs1801282 of gene PPARG promotes oxidative stress, and patients with genotype Pro 12 →Ala were less prone to complications of type 2 diabetes [7] . Although, studies on cardiomyocytes show that cells with overexpressing PPARG, more resistant to oxidative stress [8] . Today, the influence of polymorphisms rs1801282 of gene PPARG on oxidative processes and antioxidant is not in doubt. A recent study conducted by Chia-Ter Chao (2016) demonstrated Pro 12 →Ala association with increasing SOD activity in renal disease (P<0.028) [9] . We also found the intensification of LPO in carriers of alleles 12Pro in polymorphism Pro 12 →Ala of gene PPARG, whereas a significant decrease in activity of the enzyme catalase links AOC in patients with type 2 diabetes, was found as in the case of polymorphism Pro 12 →Pro of gene PPARG, and as in the presence of the allele 12Pro in this genotype [10] . Thus, the main purpose of this study was to determine the stages of formation in terms of oxidative stress, by levels of LPO and AOC in patients with type 2 diabetes, depending on the duration of the disease.
METHODS
In this study involved 138 patients, of which 88 were patients with type 2 diabetes (experimental group) and 50 not suffered from this pathology (control group). Patients with type 2 diabetes were divide into three groups for disease duration: 5 years, 5-10 years and more than 10 years. The material for the study was the blood of patients. Blood sampling was perform of patients in the morning on an empty stomach. To assess the activity of LPO indices defined diene conjugates (DC) and malonic dealdehid (MDA). DC content of unsaturated fatty acids in plasma were determine by Z. Placer method, in VB Gavrilov et al. modifications. MDA concentration was determine by its reaction with tiobarbitur acid with further quantitative determination of colored product on a spectrophotometer «Specord» (Germany), the MDA level expressed in mmol/g protein. Status AOC was evaluate by the activity of superoxide dismutase (SOD), catalase and the level of α-tocopherol (α-TF). To determine the level of α-TF, was used method of J. Biery and SOD -with Makarevich's method. In determining, the activity of catalase was used method for spectrophotometric measurement, catalase activity per unit of blood taken, mkkat/l.
Bold genomic DNA was performe-using reagents PureLink® Genomic DNA Kits For purification of genomic DNA, manufacturer INVITROGEN (USA), and the analysis of polymorphic DNA loci using a standardized test system TaqMan Mutation Detection Assays Life-Technology (USA). Data analysis was with polymorphisms Pro 12 →Pro intensification of LPO more pronounced during the first 5 years of disease and decreases gradually in the course of the disease (DK P=0.029; MDA P=0.048). Patients with genotype Pro 12 →Ala, front, intensification of LPO in the first 5 years and more than 10 years of disease, expressed to a lesser extent, as the MDA level significantly was not differed from the control group (P=0.635 and P=0.067 for the 5 and 10 years disease, respectively), while in 5-10 years has increased. The data is shown in Table 1 and Figure 1 . Based on the fact, that oxidative stress is -an imbalance between processes that are characterized by excessive formation of reactive oxygen and free radicals on the one hand, and AOS activity on the other, there is a need to investigate the performance of AOC.
Effect of polymorphism Pro 12 →Ala of the PPARG gene on the AOC was studied by analyzing the activity of SOD, catalase and α-TF levels in patients with type 2 diabetes for 5 years, 5-10 years and more than 10 years, depending on the genotype of the gene, obtained data presented in table 2 and figures 2 and 3.
In patients with type 2 diabetes for 5 years, significant differences between the activity of SOD was not found (P=0.12). As shown in Table  2 and Figure 2 , we found a probable decrease of performe using the statistical package MedCalc v.15.11.0 (MedCalc Software bvba, 1993-2015 years) and MedStat.
RESULTS AND DISCUSSION
During disease 5-10 years, found increased levels of DC in patients with genotype Pro 12 →Ala at 34.9%, in compared with homozygotes with allele 12Pro (P=0.01). When used univariate analysis of variance, revealed the likely decrease level of DC (P=0.029) between the groups of patients suffering from type 2 diabetes to 5 years, 5-10 years and more than 10 years wich have a gene polymorphism Pro 12 →Pro , while time, both carriers of genotype Pro 12 →Ala such a decrease was not found (P=0.204) ( Table 1) .
The level of MDA in patients suffered with type 2 diabetes for 5 years and 10 years, depending on the Pro 12 →Ala polymorphism of gene PPARG was not statistically different. And when disease duration was 5-10 years, have seen a probable increase in the level of MDA by 34.7% in patients with genotype Pro 12 →Ala, compared with native polymorphism Pro 12 →Pro (P=0.01). The study revealed the likely reduction of MDA by 21.5% in patients with genotype Pro 12 →Pro, which affected up to 5 years, 5-10 years and more than 10 years (P=0.048).
Analyzing the indicators of lipid peroxidation products (DC and MDA) in patients with type 2 diabetes for 5 years, 5-10 years and more than 10 years, depending on the genotype Pro 12 →Ala of the gene PPARG see (Figure 1 ), in patients SOD activity between patients who had genotype Pro 12 →Pro, with disease duration of 5 years, 5-10 years and more than 10 years (P=0.001), whereas patients with genotype Pro 12 →Ala such difference was not found (P=0.462). It should also pay attention to the fact, that SOD activity in patients with genotype Pro 12 →Ala, suffering from type 2 diabetes 5-10 years, was higher than in the first 5 years of the disease, though in patients, suffering over 10 years, this figure was in 2 times lower (P=0.04).
Thus, the importance of polymorphism rs1801282 of the PPARG gene is that in case of Pro 12 →Pro SOD activity decreases uniformly from the first years of disease in type 2 diabetes (P=0.001), whereas the presence of genotype Pro 12 →Ala observed significant (Student's criterion, bilateral critical region, significance at P=0.004) decrease in this level only after 10 years of disease.
Significant differences between the levels of catalase activity in patients suffering from diabetes for 5 years was not found (P=0.55). In Pro 12 →Pro genotype carriers were found significant decrease in catalase activity between 5-10 years of disease by 75% (P=0.001), and those who are ill for more than 10 years at 2,04 times (P=0.01), than was not different from Pro 12 →Ala -P=0.046. During the 10 years of the disease in carriers of genotype Pro 12 →Pro level of α-TF was no different from the control group (P=0.87) and in the case Pro 12 →Ala -was statistically lower (F=1,19; P=0.018).
The highest intensification of LPO obser ved during disease in type 2 diabetes till 5 years, Pro 12 →Pro genotype carriers with disease duration of 5-10 and over 10 years levels of LPO linear and significantly decreased, although compared with the control, remained at significantly high levels. In case of Pro 12 →Ala found a significant increase of LPO intensification during disease 5-10 years, whereas after 10 years of disease indices of lipid peroxidation products significantly reduced. AOS activity was significantly higher in carriers of genotype Pro 12 →Ala, suffering from type 2 diabetes 5-10 years, compared with Pro 12 →Pro. In patients with type 2 diabetes over 10 years, the presence of polymorphisms Pro 12 →Pro found catalase enzyme deficiency of AOC, against the background of a significantly high rates of lipid peroxidation, catalase activity significantly does not differ from the control level (F=1.19; P=0.600), instead in carriers of genotype Pro 12 →Ala this level was 2 times higher.
Probably the ligand-dependent activation of gene PPARG2 more pronounced in the presence of polymorphisms Pro 12 →Pro, as evidenced by the linear and the significantly reduction of oxidative stress (as indicators of lipid peroxidation, and both activities AOC) in the course of the disease, whereas carriers of genotype Pro 12 →Ala, had significantly higher levels of oxidative stress during 5-10 years of disease, but after 10 years of diseasesignificant reduction, which may be due to the depletion of metabolic processes. 
-ГО ТИПУ
Досліджували ефект поліморфізму rs1801282 гена PPARG на формування окисного стресу у хворих на цукровий діабет 2-го типу залежно від тривалості захворювання: до 5 років, 5-10 років та понад 10 років. Активність пере-кисного окиснення ліпідів оцінювали за концентрацією у крові дієнових кон'югатів (ДК) і малонового діальдегіду (МДА), а стан антиоксидантної системи -за активністю супероксиддисмутази, каталази та вмістом α-токоферолу. Молекулярно-генетичне дослідження було проведене методом полімеразно-ланцюгової реакції в реальному часі. Під час тривалості хвороби 5-10 років виявлено збільшення вмісту ДК та МДА у хворих з поліморфіз-мом Pro 12 →Ala на 34,9 і 34,7% відповідно порівняно з носіями Pro 12 →Pro (P=0,01). Наявність поліморфізму Pro 12 →Pro зумовлювало зниження активності каталази в перебіг захворювання 5-10 років на 75% (Р=0,001), а у тих, хто хворіє більше ніж 10 років в 2,04 раза (Р=0,01), що статистично не відрізняється від контрольного рівня (F=1,19; Р=0,600), тоді як у разі Pro 12 →Ala, ці показники були у двічі вищими. Отже, нами виявлено, що варіант Pro 12 →Ala поліморфізму rs1801282 гена PPARG приз-водить до максимального розвитку окисного стресу у хворих на цукровий діабет 2-го типу з тривалістю за-хворювання 5-10 років, а наявність Pro 12 →Pro зумовлює недостатність активності ферментативної каталазної ланки антиоксидантної системи у пацієнтів, що хворіють понад 5 років. Ключові слова: поліморфізм Pro 12 →Ala гена PPARG; rs1801282; цукровий діабет 2-го типу; окисний стрес. Исследовали эффект полиморфизма rs1801282 гена PPARG на формирование окислительного стресса у больных са-харным диабетом 2-го типа в зависимости от длительности заболевания: до 5 лет, 5-10 лет и более 10 лет. Активность перекисного окисления липидов оценивали по концент-рации в крови диеновых конъюгатов (ДК) и малонового диальдегида (МДА), а состояние антиоксидантной си-стемы -по активности супероксиддисмутазы, каталазы и содержания α-токоферола. Молекулярно-генетическое исследование было проведено методом полимеразной цепной реакции в реальном времени. В течение срока болезни 5-10 лет выявлено увеличение содержания ДК и МДА у больных с полиморфизмом Pro 12 →Ala на 34,9 и 34,7% соответственно в сравнении с носителями Pro 12 →Pro (P=0,01). Наличие полиморфизма Pro 12 →Pro приводило к снижению активности каталазы в период заболевания 5-10 лет на 75% (Р=0,001), а в тех кто болеет более 10 лет в 2,04 раза (Р=0,01), что статистически не отличается от контрольного уровня (F=1,19; Р=0,600), тогда как в случае Pro 12 →Ala, эти показатели были в два раза выше. Таким образом, нами выявлено, что вариант Pro 12 →Ala-полиморфизма rs1801282 гена PPARG приво-дит к максимальному развитию окислительного стресса у больных сахарным диабетом 2-го типа с длительностью заболевания 5-10 лет, а наличие Pro 12 →Pro обусловливает недостаточность активности ферментативного каталаз ного зве на антиоксидантной системы у пациентов, страдаю щих более 5 лет. Ключевые слова: полиморфизм Pro 12 →Ala гена PPARG; rs1801282; сахарный диабет 2-го типа; окислительный стресс
